Search Results

DCB Therapy Studied for Femoropopliteal Occlusive Disease

August 11, 2015—Gunnar Tepe, MD, et al published findings from an analysis of the association of patient, lesion, and procedure variables, including calcification, with late lumen loss (LLL) after drug-coated balloon (DCB) therapy in patients with femoropopliteal arterial disease.

Medtronic’s In.Pact Admiral DCB Demonstrates Safety and Effectiveness at 5 Years in CTO, LL, ISR Cohorts of IN.PACT Global Study

October 5, 2021—Gunnar Tepe, MD, presented long-term safety and effectiveness follow-up outcomes of three independent prespecified cohorts in the IN.PACT Global study of the In.Pact Admiral drug-coated balloon (DCB; Medtronic): femoropopliteal chronic total occlusion (CTO), long lesion (LL), and de novo in-stent restenosis (ISR) in real-world patients.

One-Year CONSEQUENT Data Published for B. Braun's SeQuent Please Over-the-Wire DCB

June 28, 2017—The 6- and 12-month angiographic and clinical outcomes from the CONSEQUENT trial were published by Gunnar Tepe, MD, et al online in CardioVascular and Interventional Radiology.

Published IN.PACT SFA Data Support Medtronic's In.Pact Admiral DCB

December 22, 2014—Medtronic, Inc. announced that the results of IN.PACT SFA I and IN.PACT SFA II, the landmark studies of the company’s In.Pact Admiral drug-coated balloon (DCB), were published by Principal Investigator Gunnar Tepe, MD, et al.

One-Year IN.PACT SFA Results Show Improved Outcomes for Medtronic's Drug-Coated Balloon Versus Standard PTA

April 5, 2014—Twelve-month results from the IN.PACT SFA trial studying the In.Pact Admiral drug-coated balloon (DCB) (Medtronic, Inc., Minneapolis, MN) were presented at the Charing Cross international symposium in London.

Preclinical Study Evaluates Primary Lesion Treatment With CSI's Orbital Atherectomy System Before Drug Delivery in Calcified PAD

May 20, 2015—CBSET, a preclinical biomedical research institute, announced findings from a cadaver study suggesting that modification of atherosclerotic plaque with the Diamondback 360 orbital atherectomy system (Cardiovascular Systems, Inc. [CSI]) improved drug uptake in calcified peripheral lesions. Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, stated in CBSET's announcement, “This preclinical study could have a significant clinical impact by demonstrating improved drug delivery after modification of calcified lesions.” The study results were presented by CBSET Chairman Elazer Edelman, MD, in a dedicated session on peripheral interventions at the EuroPCR 2015 conference being held May 19–22 in Paris, France.

Biotronik's Technology Evaluated for Reduction of Metal Burden in SFA Treatment

January 31, 2018—Biotronik announced that data demonstrating that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce restenosis rates were presented during a company-sponsored symposium chaired by Jos van den Berg, MD, at LINC 2018: the Leipzig Interventional Course, held January 30 to February 2 in Leipzig, Germany.

Enrollment Begins in Covidien's DEFINITIVE AR Study

August 3, 2011—Covidien (Mansfield, MA) announced the start of patient enrollment in the DEFINITIVE AR antirestenosis study.

Two-Year Outcomes Announced From BIOLUX P-III Registry

February 12, 2019—Biotronik announced 24-month data from the BIOLUX P-III registry, which were first presented at LINC, the Leipzig Interventional Course held January 22–25, 2019, in Leipzig, Germany.

Medtronic Announces Plans for IN.PACT Global SFA Drug-Eluting Balloon Study

April 17, 2012—Medtronic, Inc. (Minneapolis, MN) announced that it will be commencing the IN.PACT Global superficial femoral artery (SFA) clinical study.